Lexeo Therapeutics (LXEO) Change in Account Payables (2022 - 2026)

Lexeo Therapeutics has reported Change in Account Payables for 5 years, with the latest figure at -$1.6 million in Q1 2026.

• Quarterly Change in Account Payables fell 131.03% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.3 million (down 220.6% YoY) and the FY2025 annual result came in at -$1.6 million, down 165.64% from the prior year.
• Change in Account Payables slipped to -$1.6 million in Q1 2026 per LXEO's latest filing, from $200000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $8.4 million in Q2 2025 and troughed at -$15.3 million in Q3 2025.
• A 5-year average of -$155714.3 and a median of $342000.0 in 2023 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2024 and 2025: Change in Account Payables surged 838.62% in 2024, then sank 660.91% in 2025.
• Over 5 years, Change in Account Payables stood at -$1.2 million in 2022, then surged by 132.27% to $394000.0 in 2023, then slumped by 618.27% to -$2.0 million in 2024, then jumped by 109.79% to $200000.0 in 2025, then sank by 898.0% to -$1.6 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$1.6 million, $200000.0, and -$15.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.